Cancer-associated hypercalcemia treated with intravenous diphosphonates: A survival and prognostic factor analysis

Supportive Care in Cancer

Volumn 16, Issue 4, 2008, Pages 387-392

  Penel, Nicolas ^a,b   Dewas, Sylvain ^a   Doutrelant, Philippe ^a   Clisant, Stéphanie ^a   Yazdanpanah, Yazdan ^b   Adenis, Antoine ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIV LILLE   (France)

Author keywords

Cancer; Diphosphonates; Hypercalcemia; Prognosis; Supportive care

Indexed keywords

ALBUMIN; CALCIUM; ETIDRONIC ACID;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CANCER ASSOCIATED HYPERCALCEMIA; CANCER PATIENT; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; HUMAN; HYPERCALCEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; HYPERCALCEMIA; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 43449095037     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0322-z     Document Type: Article

References (27)

1. Besarb A, Caro JF (1978) Mechanisms of hypercalcemia in malignancy. Cancer 41:2276-2285
2. Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ (1990) Hypercalcemia in patients with disseminated breast cancer. Acta Oncol 29:577-580
3. Body JJ, Borkowski A, Cleeren A et al (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 4:1177-1183
4. Nussbaum SR, Younger J, Vandepol CJ et al (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297-304
5. Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of biphosphonates. Cancer 88:2961-2978
6. Major P, Lhortolary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy a pooled analysis of two-randomized controlled clinical trials. J Clin Oncol 19:558-567
7. Monno S, Nagata A, Furuta S (1987) Hypercalcemia of cancer in the aerodigestive tract. J Clin Gastroenterol 9:78-82
8. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT (1990) Cancer-associated hypercalcemia morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112:499-504
9. Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF, Warrell RP Jr (2006) Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 12:47-53
10. Kristensen B, Ejlersten B, Mouridsen HT, Loft H (1998) Survival in breast cancer patients after the first episode of hypercalcemia. J Intern Med 244:189-198
11. Payne RB, Carver ME, Morgan DB (1979) Interpretation of serum total calcium effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 32:56-60
12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
13. Mantel N (1966) Estimation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170
14. Cox D (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187-220
15. Chasan SA, Pothel LR, Huben RP (1989) Management and prognostic significance of hypercalcemia in renal cell carcinomas. J Urology 33:167-170
16. Degardin M, N'Guyen M, Beaurin D et al (1995) Hypercalcémie et carcinomes épidermoides des voies aéro-digestives supérieures. Incidence et pronostic. Bull Cancer 82:975-980
17. Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS (1991) The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 145:248-250
18. Penel N Berthon C, Everard F et al (2005) Prognosis of hypercalcemia in aerodigestive tract cancers Study of 136 recent cases. Oral Oncology 41:884-889
19. Wysolmerski JJ, Broadus AE (1994) Hypercalcemia of malignancy: the central role of parathyroid hormone related protein. Ann Rev Med 45:189-200
20. Skrabanek P, Mc Partlin J, Powell D (1980) Tumor hypercalcemia and "ectopic" hyperparathyroidism". Medicine 59:262-282
21. Wimalawansa SJ (1994) Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated. with diphosphonate. Cancer 73:2223-2230
22. Walls J, Ratcliffe WA, Howell A, Bundred NJ (1994) Response to intravenous biphosphonate therapy in hypercalcemic patients without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 70:169-172
23. Gurney H, Grill V, Martin TJ (1993) Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia. Lancet 341:1611-1613
24. De Wits S, Cleton FJ (1994) Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 120:610-614
25. Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival with cancer and hypercalcemia. Am J Med 115:115-121
26. Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukemia Working Party. J Clin Oncol 23:9219-9226
27. Ling PJ, A'Hern RP, Hardy JR (1995) Analysis of survival following treatment of tumour-induced hypercalcemia with intravenous pamidronate (APD). Br J Cancer 72:206-209